|Chennai||Rs. 27770.00 (-0.14%)|
|Mumbai||Rs. 29200.00 (2.31%)|
|Delhi||Rs. 27900.00 (-0.36%)|
|Kolkata||Rs. 28270.00 (1%)|
|Kerala||Rs. 27050.00 (-0.37%)|
|Bangalore||Rs. 27550.00 (1.66%)|
|Hyderabad||Rs. 27770.00 (-0.14%)|
Dr Reddy's Laboratories , India's No.2 drugmaker by sales, reported a larger-than-expected 29.2 percent drop in quarterly net profit as sales in its key North America market remained muted.
Consolidated net profit fell to 3.63 billion rupees ($67.5 million) in the fiscal third quarter ended December, from 5.13 billion rupees a year earlier, the drugmaker said on Thursday. Income from sales and services grew 3.5 percent to 28.65 billion rupees.
Analysts on an average had forecast a net profit of 4.42 billion rupees on net sales of 29.65 billion rupees, according Thomson Reuters I/B/E/S.
Valued $6 billion, shares in ies were down 1.3 percent to 1,879.30 rupees by 0825 GMT when the Mumbai market was down 0.12 percent.